2019 Annual Meeting | C181 - Treatment of Pediatric Multiple Sclerosis in the Current Era

Date Wednesday 05/08/19

Time 01:00 PM - 03:00 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Brenda L. Banwell, MD, FAAN

Topic(s) Child Neurology and Developmental Neurology, Multiple Sclerosis

Learning Objectives Attendees should feel competent in the approach to diagnosis of MS in children; will be provided with strategies to investigate disorders considered in the differential, in order to meet the requirement of "excluding other diagnoses" prior to conferring the diagnosis of MS; be able to discuss up-to-date information regarding currently available therapeutic agents for pediatric MS, including dosing and safety monitoring; and be informed regarding upcoming clinical trials for pediatric MS.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Advanced

Recommended Audience Fellow, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM EDT	Introduction	Introduction and Welcome Brenda L. Banwell, MD, FAAN
01:05 PM - 01:45 PM EDT	Speaker	Diagnosis of Pediatric MS: Considerations of Treatment Selection Brenda L. Banwell, MD, FAAN
01:45 PM - 02:15 PM EDT	Speaker	PARADIGMS Trial: Implications for Pediatric MS Tanuja Chitnis, MD, FAAN
02:15 PM - 02:45 PM EDT	Speaker	Upcoming Clinical Trials in Pediatric MS Emmanuelle Waubant, MD, PhD, FAAN
02:45 PM - 03:00 PM EDT	Discussion	Audience Discussion Brenda L. Banwell, MD, FAAN, Tanuja Chitnis, MD, FAAN, Emmanuelle Waubant, MD, PhD, FAAN

Faculty Disclosures
Brenda L. Banwell, MD, FAAN	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Tanuja Chitnis, MD, FAAN	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.
Emmanuelle Waubant, MD, PhD, FAAN	The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��